SSSvitlana Slobodianyk

Svitlana Slobodianyk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Svitlana Slobodianyk has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Safeguarding patients’ vision over eight decades: 80 years of the Oftalmologicheskii Zhurnal

    by Nataliya Pasyechnikova, Svitlana Poliakova, Svitlana Slobodianyk, Olena Stoilovska, Hanna Arkusha

    In the history of Ukrainian medicine, there are journals that have become not just media to distribute publications, but true chronicles of particular fields of science. This is what the Ophthalmological Journal was and remains for Ukrainian ophthalmology. The journal was founded by Acad. V.P. Filatov as early as 1946, and has been shaping the face of Ukrainian ophthalmology for decades. Today we celebrate a significant milestone, the 80th anniversary of the journal.

  • Open Access

    REDUCTION OF THE RISK OF GLAUCOMATOUS OPTIC NEUROPATHY PROGRESSION AFTER COMPLEX NEUROPROTECTION

    by O. V. Guzun, O. S. Zadorozhnyy, N. V. Konovalova, N. I. Khramenko, V. A. Vasiuta, S. B. Slobodianyk

    The problem of glaucomatous neurodegeneration with progressive death of retinal ganglion cells (RGCs) and development of visual field defects can lead to irreversible blindness. In this regard, there is a need to search for effective strategies for neuroprotection of RGCs.Objective. To study the risk of glaucomatous optic neuropathy (GON) progression in patients with primary open-angle glaucoma (POAG) after complex neuroprotection by photobiomodulation (PBM) and nutraceutical formula AREDS2 with ω-3 polyunsaturated fatty acids (PUFA) enhancement and resveratrol for a 12- month follow-up.Material and methods. A total of 137 patients (137 eyes) diagnosed with early or advanced POAG were examined. The main group (group 1) included 74 patients, the control group (group 2) – 63 patients. All patients underwent PBM therapy. Patients of group 1 were additionally recommended the nutraceutical formula AREDS2, enriched with ω-3 PUFA and resveratrol 60 mg (Resvega® Forte; Théa, France; 2 capsules per day) for 12 months. Using Cox regression, the relative risk (cumulative risk function) for predicting the progression of GON was calculated.Results. After 12 months of observation, the median POAG in group 1 exceeded the initial level by 15%. Stabilization and a tendency to improve the parameters of retinal morphometry, Humphrey computer perimetry, as well as an improvement in intraocular blood volume by 24% (p = 0.001) were noted. In the control group, deterioration in all parameters was noted.Conclusions. Complex neuroprotection using PBM and taking the AREDS2 nutraceutical with ω-3 PUFA and resveratrol (60 mg) for 12 months in patients with POAG can reduce the relative risk of progression of GON by 2.27 times (95% DI 1, 38–3.75). Статтю присвячено актуальній проблемі глаукомної нейродегенерації та пошуку ефективних стратегій нейропротекції. Фотобіомодуляція (ФБМ) з антиоксидантною дією ресвератролу є перспективним методом нейропротекції, що дає змогу обґрунтувати його застосування за глаукомної оптичної нейропатії (ГОН) як комплексної нейропротекторної терапії. Використання ФБМ сітківки / диска зорового нерву з 12-місячним прийманням нутрицевтика формули AREDS2, посиленого ω-3 ПНЖК і ресвератролом (60 мг), у хворих на первинну відкритокутову глаукому дає можливість у 2,27 раза знизити відносний ризик прогресування ГОН (95 % DI 1,38–3,75), завдяки покращенню об’ємного внутрішньоочного кровообігу, підвищенню провідності в нервових волокнах зорового нерву з покращенням загальної світлової чутливості зорового аналізатора, та стабілізувати морфометричні показники зорового аналізатора й максимально кориговану гостроту зору.